Asia-Pacific Tulathromycin Market Size & Outlook, 2025-2033

Asia-Pacific Tulathromycin Market Size

The Asia-Pacific tulathromycin market size was valued at USD 1.18 billion in 2024 and is projected to reach from USD 1.28 billion in 2025 to USD 2.46 billion by 2033, growing at a CAGR of 8.5% during the forecast period (2025-2033).

Two generic tulathromycin injectable medicines have just received FDA approval in 2021 for the treatment and management of specific diseases in both cattle and swine.

Bovine respiratory disease (BRD) in cattle and swine respiratory disease in pigs are both treatable with tulathromycin, a macrolide antibiotic. Pfizer Inc. sells it under the brand name Draxxin. The 100-mg dose is contained in an injectable solution.

The Asia-Pacific tulathromycin market is driven by rising veterinary healthcare awareness. The entry of generic tulathromycin acts as a restraint on this market. On the other hand, the focus on animal welfare acts as an opportunity for the tulathromycin market.

To get more insights about this report Download Free Sample Report

Asia-Pacific Tulathromycin Market Driving Factors

Rising Veterinary Healthcare Awareness

Livestock producers in the Asia-Pacific region increasingly recognize the significance of preventive healthcare measures to ensure the well-being and productivity of their animals. They know that keeping their cattle healthy increases productivity and reduces financial losses. As a result, they are actively looking for ways to shield their animals from illness and treat it, which includes using antibiotics like tulathromycin.

In addition, pet owners in the area are starting to pay greater attention to the health and welfare of their animals. They know the significance of giving their dogs the proper care to ensure a high quality of life. Veterinary clinics and other pet healthcare providers play a critical role in educating the public on the value of routine checkups, vaccines, and antibiotics when necessary.

The rise in veterinary healthcare awareness is also supported by educational initiatives and awareness campaigns conducted by government agencies, veterinary associations, and pharmaceutical companies. These initiatives seek to inform those who raise livestock, those who keep pets, and the general public about the value of prudent antibiotic usage, the risks of antibiotic resistance, and the advantages of early detection and treatment.

Market Restraining Factors

Entry of Generic Tulathromycin

Bovine respiratory disease (BRD) caused by Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis is treated with the generic drugs Macrosyn and Increxxa in beef and non-lactating dairy cattle, suckling calves, dairy calves, and veal calves. Additionally, it's used to treat swine respiratory disease (SRD), which is a condition that affects swine and is brought on by pathogens like Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica, Haemophilus parasuis, and Mycoplasma hyopneumoniae.

The approved brand-name drug product Draxxin, first approved in 2005, shares the same active component (tulathromycin) with Macrosyn and Increxxa in the same dose form and concentration. These two generic medications are anticipated to reduce the demand for tulathromycin market in the next few years. By consuming some of the demand for the name-brand Draxxin, the demand for generic medicines will increase more quickly.

Market Opportunity

Focus on Animal Welfare

Given the increasing attention paid to animal welfare, the Asia-Pacific tulathromycin market has a sizable opportunity. Consumers are looking for products that reflect their ideals and give ethical treatment of animals more weight. In the veterinary pharmaceutical industry, where customers are looking for antibiotics and other treatments that improve animals’ general health and well-being, this shift in consumer preferences is also present.

For the tulathromycin market, highlighting the antibiotic's role in improving animal health and welfare can help companies stand out and attract conscious consumers. Tulathromycin is a powerful antibiotic that can treat and prevent bacterial and respiratory infections in animals, which is essential for maintaining animal health and reducing suffering.

Additionally, businesses can participate in transparent and traceable supply chains, disclosing where tulathromycin is sourced and guaranteeing its manufacture complies with stringent animal welfare requirements. This may entail collaborating closely with livestock farmers to ensure cattle are raised in conditions that support their well-being, such as having access to enough space, wholesome food, and veterinary treatment. By exhibiting these initiatives, companies can attract customers who are concerned about the conditions in which animals are raised and look for products that contribute to their well-being.

Country Insights

The Asia-Pacific tulathromycin market is segmented based on the country: China, India, Japan, Southeast Asia, Korea, Australia, and the Rest of Asia-Pacific. China dominates the country's market and is expected to grow at a CAGR of 8.9% during the forecast period.

The second-largest market for tulathromycin is in Asia-Pacific. China and India currently hold the majority of the market. Cattle and swine have the highest population, which is primarily to blame.

• For instance, China is home to more than 50% of the world's pigs. According to the most recent report from China's Ministry of Agriculture and Rural Affairs, domestic pigs will top 440 million by the end of 2021. In addition, the nation has a significant presence of cattle, totaling about 91.1 million.

India Tulathromycin Market Trends

India, on the other hand, is the largest nation with the highest population of cattle. Over 192 million people will live there by 2020, rising quickly. It has been noted that more farmers are diversifying their sources of income and turning to dairy farming as a secondary source of income in addition to traditional farming. As a result, tulathromycin demand is growing at a robust CAGR.

Most of the demand for tulathromycin is imported from China and India.

Animal Insights

Cattle dominated the market and is expected to register a CAGR of 8.9% over the forecast period. Tulathromycin treats and prevents bovine respiratory disease (BRD) caused by Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis in cattle. Respiratory disease plays a significant role in weaned calf mortality, and bovine respiratory disease (BRD) morbidity affects survivability and reduces dairy performance later in life.

List of key players in Asia-Pacific Tulathromycin Market

1. Zoetis
2. Zhejiang Genebest Pharmaceutical
3. Wisdom Pharmaceutical
4. Amicogen Biopharm
5. Hubei Honch Pharmaceutical
6. Livzon New North River Pharmaceutical
7. AVF Chemical Industrial
8. Jiangsu Lingyun Pharmaceutical

To get more findings about this report Download Market Share

Recent Developments

• April 2023: Amicogen Biopharm announced that its new tulathromycin product, Tulathromycin Powder for Suspension, had been approved by the CFDA. A once-daily oral medication called tulathromycin powder for suspension treats BRD in cattle.